


## As Three More Studies Show Negative Vaccine Effectiveness, When Will Health Authorities Face Up to What the Data is Telling Us?

By <u>Will Jones</u> Global Research, December 30, 2021 <u>dailysceptic.org</u>

The last two weeks have brought three new studies finding negative efficacy for two vaccine doses, meaning the vaccinated are more likely to be infected than the unvaccinated.

These are study findings, not raw data, so have been adjusted for various biases and confounders, making it harder to dismiss them as anomalous or skewed.






The first is a <u>pre-print study</u> from Denmark, published on December 23rd, which looked at nearly all PCR-positive SARS-CoV-2 infections in Denmark from November 20th to December 12th and investigated them to see if they were likely to be the Omicron variant. By comparing the vaccination status of those infected, the researchers found a vaccine effectiveness against the Omicron variant of minus-76.5% for Pfizer and minus-39.3% for Moderna three months after double vaccination (see chart above), meaning the doublevaccinated were considerably more likely to be infected than the unvaccinated. They found the vaccine effectiveness against Omicron was significantly lower than against Delta, with Pfizer vaccine effectiveness at 53.8% and Moderna at 65% against Delta after three months. They reported that a third dose of Pfizer got vaccine effectiveness against Omicron back up to 54.6%, at least for a month. The full results are in the table below.

	Pfizer – BNT162b2				Moderna - mRNA-1273			
Time since vaccine	Omicron		Delta		Omicron		Delta	
protection	Cases	VE, % (95% CI)	Cases	VE, % (95% CI)	Cases	VE, % (95% CI)	Cases	VE, % (95% CI)
1-30 days	14	55.2 (23.5; 73.7)	171	86.7 (84.6; 88.6)	4	36.7 (-69.9; 76.4)	29	88.2 (83.1; 91.8)
31-60 days	32	16.1 (-20.8; 41.7)	454	80.9 (79.0; 82.6)	8	30.0 (-41.3; 65.4)	116	81.5 (77.7; 84.6)
61-90 days	145	9.8 (-10.0; 26.1)	3,177	72.8 (71.7; 73.8)	48	4.2 (-30.8; 29.8)	1,037	72.2 (70.4; 74.0)
91-150 days	2,851	-76.5 (-95.3;-59.5)	34,947	53.8 (52.9; 54.6)	393	-39.3 (-61.6;-20.0)	3,459	65.0 (63.6; 66.3)
1-30 days after	booster va	ccination						
protection	29	54.6 (30.4; 70.4)	453	81.2 (79.2; 82.9)	-	-	5	82.8 (58.8; 92.9)

CI = confidence intervals; VE = vaccine effectiveness. VE estimates adjusted for 10-year age groups, sex and region (five geographical regions). Vaccine protection was assumed 14 days post 2<sup>nd</sup> dose. Insufficient data to estimate mRNA-1273 booster VE against Omicron.

Hansen et al.


The <u>latest vaccine effectiveness study from the UKHSA</u> confirms these results. Against Omicron, the UKHSA reports zero or negative vaccine effectiveness from a double-dose of all three vaccines (AstraZeneca, Pfizer and Moderna) after five months. The third dose takes it up again, but only into the 40-60% range, and dropping fast.



Delta

Time since Vaccine (weeks)

AstraZeneca



ò 0 -20 -40 -60 15-19 2 - 45-9 10-14 O Omicron Time since Dose 2 (weeks) Delta

A new study in Eurosurveillance from Norway also backs up the observation of negative vaccine effectiveness against Omicron, with a higher proportion of those who tested positive in the particular outbreak in the study being double-vaccinated than those who did not test positive (98% versus 93%).

þ

20-24

Some studies had already found negative vaccine effectiveness against Delta, in line with

Moderna

the <u>unadjusted figures from the UKHSA</u>, though many people had dismissed these results as anomalous or biased. With Omicron, the reports of negative efficacy are becoming impossible to ignore, with even the UKHSA publishing graphs showing it after three months on two doses. At some point, health authorities are going to need to grapple with what the data is showing on this and stop pretending it isn't there

The original source of this article is <u>dailysceptic.org</u> Copyright © <u>Will Jones</u>, <u>dailysceptic.org</u>, 2021

## **Comment on Global Research Articles on our Facebook page**

## **Become a Member of Global Research**

Articles by: Will Jones

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca